Search

Your search keyword '"Gan, Shlomit"' showing total 9 results
Start Over Author "Gan, Shlomit"
9 results on '"Gan, Shlomit"'

3. Heparanase Expression in Malignant Salivary Gland Tumors Inversely Correlates with Long-Term Survival1

Author

Ben-Izhak, Ofer, Kaplan-Cohen, Victoria, Ilan, Neta, Gan, Shlomit, Vlodavsky, Israel, and Nagler, Rafael

Subjects
Male, Adenocarcinoma, Middle Aged, Prognosis, Salivary Gland Neoplasms, Immunohistochemistry, Survival Analysis, Up-Regulation, Carcinoma, Squamous Cell, Humans, Female, Research Article, Aged, Glucuronidase
Abstract

Upregulation of the endo-beta-D-glucuronidase, heparanase, was noted in an increasing number of human malignancies. Heparanase expression correlated with enhanced local and distant metastatic spread, increased vascular density, and reduced postoperative survival.We analyzed heparanase expression in 60 patients (aged 59 +/- 17 years) with malignant salivary tumors (39 males and 21 females) using immunohistochemistry. We applied antiheparanase antibody 733, which has previously been shown to preferentially recognize a 50-kDa active heparanase subunit over a 65-kDa latent enzyme. Thus, immunostaining can directly be correlated with enzymatic activity.Heparanase staining was positive (0) in 70% of tumors (42 of 60 patients) and was negative (0) in the remaining 30% (18 patients). The cumulative survival of patients diagnosed as heparanase-negative (n = 18) at 300 months was 70% (95% confidence interval = 35-88). In contrast, the cumulative survival of patients diagnosed as heparanase-positive (n = 42) at 300 months was 0% (statistically significant difference, P = .035).Heparanase expression levels inversely correlate with the survival rates of salivary gland cancer patients, clearly indicating that heparanase is a reliable prognostic factor for this malignancy and an attractive target for anticancer drug development.

Published
2006

4. A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN-α) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation

Author

Nagler, Arnon, primary, Berger, Raanan, additional, Ackerstein, Aliza, additional, Czyz, Jaroslaw A., additional, Diez-Martin, Jose Luis, additional, Naparstek, Elizabeth, additional, Or, Reuven, additional, Gan, Shlomit, additional, Shimoni, Avichai, additional, and Slavin, Shimon, additional

Published
2010
Full Text
View/download PDF

9. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.

Author

Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E, Or R, Gan S, Shimoni A, and Slavin S

Subjects
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Combined Modality Therapy, Female, Fever chemically induced, Hodgkin Disease pathology, Humans, Immunotherapy, Interferon Type I administration & dosage, Interleukin-2 administration & dosage, Interleukin-2 adverse effects, Interleukin-2 genetics, Lymphoma, Non-Hodgkin pathology, Male, Middle Aged, Multivariate Analysis, Nausea chemically induced, Prospective Studies, Recombinant Proteins administration & dosage, Recombinant Proteins adverse effects, Survival Analysis, Transplantation, Autologous, Treatment Outcome, Vomiting chemically induced, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease therapy, Lymphoma, Non-Hodgkin therapy, Stem Cell Transplantation methods
Abstract

We have earlier shown an advantage in overall survival for malignant lymphoma (ML) patients who received combined Interleukin-2 (rIL-2) and interferon alpha (IFN-alpha) immunotherapy after autologous stem cell transplantation (AutoSCT) in comparison with historic controls. On the basis of these results, we initiated a control prospective randomized multicenter 2-arm study, comparing the same combined immunotherapy treatment versus control for patients with malignant lymphoma after AutoSCT. One hundred nine patients were included in this study. After AutoSCT, patients were randomized either to the treatment group or to the control group. Patients in the treatment group received daily subcutaneous injections of rIL-2 6x10 IU/m/d for 5 consecutive days followed by 2-weeks rest period. Subsequently, they were treated daily with rIL-2 6x10 IU/m/d combined with INF-alpha 3x10 U/d for 5 consecutive days per week for 4 consecutive weeks. After 4 weeks of rest, IFN-alpha 3x10 U was administered for the next 6 months 3 times per week. Patients in the control group were followed up at the outpatient clinic. There was a significant enhancement of survival (P=0.05) and a clear trend in disease-free survival in favor of NHL patients receiving post-AutoSCT immunotherapy, in comparison with the control group. Eighty-nine percent of patients with NHL treated with immunotherapy were alive and 64% were disease free. In the control group, 66% of patients survived and 46% were disease free. Among the HL patients no significant differences were observed regarding survival, disease-free survival, and relapse rate. No serious toxicity events were observed. These results suggest that outpatient administered immunotherapy with IFN-alpha and rIL-2 is relatively well tolerated and may intensify remission in NHL patients, but not HL patients after AutoSCT.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results